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ment of AD and promising advances in health technologies have the potential to 
significantly impact on the burden of the disease. However, alongside treatment 
advances it is important to improve the evaluation framework if we are to capture 
the potential benefits to people with AD. Methods to model disease progression 
over time, for use in comparative and cost-effectiveness analyses (CEA), is a pri-
ority area for further research. The objective in this research is to develop a new 
framework for modeling AD progression over time using the three main symptom 
domains of cognitive function, behaviour and mood, and functioning. Methods: 
Development of a descriptive system, comprising a set of health states for AD, using 
the three symptom domains. Statistical modeling of disease progression through 
states over time, using US data from the National Alzheimer’s Coordinating Center 
(NACC) (n= 3009). The model is tested in a decision-analytic context, using time to 
progression and a cost-per-QALY framework. Results: A 20-state disease progres-
sion pathway has been developed using multi-variate health states described using 
the three symptom domains. Transition probabilities and hazard rates have been 
estimated to model progression over time through the multi-variate descriptive 
system. In a baseline model over a 5-year timeframe, using mild-to-moderate AD 
starting states, 78% of people progressed to health states considered severe on at 
least one of the symptoms (46% severe for cognition). In a HTA context simulating a 
treatment with a modest effect the modeling framework predicted significant QALY 
differences between control and treatment over 5-years. ConClusions: This new 
modeling framework shows promise and presents a broader opportunity to capture 
the impacts of treatment over time using a range of symptom domains.
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objeCtives: The National Institute for Health and Care Excellence recommends 
utilising external data to evaluate the validity of extrapolation beyond trial follow-
up. The objective was to demonstrate the use of external data to guide long-term 
survival predictions where only short-term trial data are available. Methods: 
Four-year patient-level data for chlorambucil and ofatumumab+chlorambucil from 
the COMPLEMENT-1 trial were available; the survival rate was over 70% at four 
years. Published 18-year Kaplan-Meier data for chlorambucil from the C9011 study, 
which compared fludarabine and chlorambucil, were used to simulate a patient-
level dataset. These data were not used directly as outcomes have improved sub-
stantially since patients were enrolled (1990-1994) and the chlorambucil dosing 
regimens differed. However the curve was used to guide the extrapolation of the 
COMPLEMENT-1 data using a three-stage approach: 1) Survival functions were fitted 
for the COMPLEMENT-1 and C9011 chlorambucil arms with an indicator for study. 
2) The average treatment effect (chlorambucil versus ofatumumab+chlorambucil) 
was estimated from survival analysis for both arms of COMPLEMENT-1 and 
the C9011 chlorambucil arm, with indicators for treatment and study. 3) For 
ofatumumab+chlorambucil, long-term survival was estimated by applying the 
treatment effect from stage 2 to the function for chlorambucil from stage 1. 
Exponential, gamma, Weibull, log-normal, log-logistic and Gompertz functions were 
fitted. Results: Weibull, Gompertz, and gamma functions provided reasonable fits 
during trial follow-up and plausible extrapolations (assessed by Akaike information 
criterion, Bayesian information criterion, graphical diagnostics, and expert clinical 
opinion). Survival predictions were markedly lower than conventional functions 
fitted to COMPLEMENT-1 data only (e.g. Weibull predictions for chlorambucil at 20 
years were 8% vs 26%, respectively). ConClusions: Using long-term external data 
to guide the extrapolation provided plausible predictions for chlorambucil upon 
which alternative scenarios for the continuation of treatment effect observed in 
COMPLEMENT-1 could be explored.
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objeCtives: Epidemiological projections sizing patient populations are fundamen-
tal to budget impact analyses and market forecasting. When disease risk evolves 
over time, as in the case of epidemiological transition, using historical estimates in 
epidemiological projection becomes unjustified. Incorporation of additional vari-
ables that model evolving risk may allow for more reliable forecasts. The hypothesis 
that gross domestic product per capita (GDP) is correlated with disease risk was 
tested for a variety of cancers using global epidemiological and economic data-
sets. Methods: Age-standardized incidence for 18 cancer sites across 188 countries 
was retrieved from the International Agency for Research against Cancer for the 
years 1993-1997. Corresponding country-specific GDP data was collected from the 
World Bank. For each site, correlation between GDP and incidence was measured 
using R2and linear co-efficient values. Results: Risk is strongly correlated with 
GDP for all of the sites studied, with the exception of the stomach (R2= 0; p> 0.05). 
Correlation was strongest for those sites associated with diet/lifestyle factors 
prevalent in higher-income countries, namely: colorectal (R2= 0.61; p< 0.001), breast 
(R2= 0.61; p< 0.001) and lung (R2= 0.42; p< 0.001). Strong association was also seen for 
prostate (R2= 0.47; p< 0.001), although this may be explained by better case-detection 
in higher-income countries. Conversely, those cancer sites associated with infec-
tion showed a negative correlation, namely: cervix (R2= 0.33; p< 0.01), liver (R2= 0.09; 
p< 0.001) and oesophagus (R2= 0.06; p< 0.01). ConClusions: GDP is strongly asso-
ciated with cancer risk and varies by organ site in a manner concordant with the 
evolving exposures to known pathogens that characterize epidemiological transi-
tion. On the assumption that such correlation is a marker for various causal relation-
ships, and that robust economic methods underlie GDP forecasts, it is reasonable to 
conclude that these correlations could be used to make epidemiological projections 
more accurate than projections assuming constant disease risk.
economic model with ten key parameters to calculate the ICERs associated with 
various combinations of inputs. Published HTAs were reviewed to determine the 
model inputs. Extensive scenario and multiway sensitivity analyses were carried 
out to document informative patterns and relationships between parameters that 
affected the results. Results: Results showed that cancer sub-types with higher 
post-progression costs reduced a treatments likelihood of being cost-effective. The 
results also highlighted specific thresholds at which various cancer-specific case 
studies or combinations of inputs, including drug price, resulted in the drug being 
deemed not cost-effective using a threshold of £20,000 per QALY. ConClusions: 
The impact of post-progression costs can vary dependent on how these costs are 
modelled and also dependent on several factors, namely the ratios between health 
state utilities, ‘background’ costs, drug costs and the relative time spent in the 
stable and progressed disease states. It is demonstrated that, for many oncology 
treatments whose primary aim is to extend survival, this impact can be prohibitive 
to an intervention’s probability of being cost-effective.
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objeCtives: Network Meta Analyses (NMAs) are often used to parameterise efficacy 
in decision models for economic evaluation. A common source of heterogeneity 
in NMA arises from the fact that treatments may be given at different doses. This 
variation may manifest as unexplained heterogeneity in standard NMA models and 
propagates through to the decision analysis. We aim to explore how dose-response 
NMA can be used to inform cost-effectiveness analysis using a cost-utility analysis 
of treatments for acute migraine. Methods: We conducted four NMAs with differ-
ent assumptions around dose-response to inform an economic evaluation in acute 
migraine. Separate 1-level NMAs were conducted where interventions were ‘lumped’ 
at the ‘dose’, ‘treatment’ and ‘class’ levels and a multi-level NMA was conducted, 
assuming monotonic dose-response. All NMAs were used to inform effect sizes in 
an economic model; the model structure, costing methods and utility inputs from 
the NICE Headaches guideline were adopted. The NMA models were compared 
in terms of heterogeneity and Deviance Information Criteria (DIC). We report the 
results of the economic analyses using cost-effectiveness acceptability frontiers 
(CEAFs). Results: Dose-response parameterisation lead to NMA models with lower 
heterogeneity and better fit. Different dose-response parameterisations substan-
tially changed the resource allocation decision, particularly at lower willingness 
to pay thresholds. For the more complex NMA model, it is unclear from a decision 
making perspective which effect size estimates should be selected as inputs to 
the decision model and we show that careful consideration should be given to the 
relevance of individual doses and confounding bias. ConClusions: Dose-response 
NMA provides a useful and arguably more appropriate method for conducting NMA 
for decision analysis. Careful consideration should be given to how to treat doses of 
the same intervention in NMA since different parameterisations may lead to biased 
effect sizes and sub-optimal conclusions around cost-effectiveness.
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objeCtives: Majority of established pharmaceutical markets use pricing rules that 
reference products both across (international reference pricing; IRP) and within 
(therapeutic reference pricing; TRP) country-lines. Some markets, such as the UK, 
use no such rules and freely price therapies. IRP and TRP are used as effective 
measures to control price of pharmaceutical products. However, understanding the 
impact on a global level is considered highly complex, due to each market using 
different legislations and mechanisms. There is a growing need to better understand 
the impact of IRP and TRP on the decay of pharmaceutical drug prices and their 
effects on launch prices and sequencing across multiple markets. Methods: We 
utilized a model to simulate the impact of IRP and TRP, as well as parallel trade, to 
quantitatively assess impact on drug prices across 40 markets (EU28, Switzerland, 
Russia, Iceland, Norway, Turkey, Israel, Brazil, Japan, South Korea, Australia, Canada 
and USA). The model uses simulating annealing parameters to also yield optimized 
launch sequences in all markets. Results: Outputs of the model include impact to 
volume, price and revenue as well as parallel trade. Using a dynamic launch map, 
the model provides optimized price and launch sequence of a given pharmaceutical 
product. Within a set window, the launch and reimbursement dates were optimized 
based on a divergent set of rules and country baskets, often differing from manu-
facturers expected launch prices and sequences. While manufacturers are often 
able to secure higher price for therapies in free-price markets, the model clearly 
demonstrates the spill-over impact of referencing (both formally and informally) 
across countries and within therapeutic groups. ConClusions: Previously, launch 
sequences were optimized based on the implications on major markets. However, an 
expansive model looking at large number of markets that employ varying IRP and 
TRP rules will assist manufacturers in identifying an optimized price and launch 
sequence strategy.
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MODelinG Disease PROGRessiOn in alzheiMeR’s DeMentia tO infORM 
hta (Cea)
Green C., Zhang S.
Exeter University, Exeter, UK
objeCtives: Alzheimer’s dementia (AD) poses a significant challenge to health care 
systems around the world. Whilst treatment options are currently limited, with no 
effective disease modifying treatment, new advances in diagnosis and manage-
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dence interval 67-83%) of instances compared with the control method (25%, 95%CI 
17-33%), and among 83% (95%CI 76-91%) of positively-GDP-associated cancers 
compared with 17% (95%CI 9-24%) for the control method. There was no significant 
difference between the two methods for negatively-GDP-associated cancers. In 
terms of the relative magnitude of change compared to the actual incidences, there 
was no significant difference between the GDP-based forecast incidences and the 
control (mean magnitude difference 3.8%, 95% CI -3.5% - 11.0%). ConClusions: 
During epidemiological transition, cancer incidence is unlikely to remain static 
and so developing a proxy variable to evaluate risk over time is important. Using 
GDP as a proxy variable is preferable to the alternative of projecting historical 
values forward unchanged in terms of directional effect. However our study found 
no significant difference in terms of relative magnitude of the change over time. 
This latter result may be due to a small sample size of registries, indicating a need 
for further research.
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objeCtives: Bevacizumab (BEV) has proven to be efficacious to delay ovarian can-
cer progression and in controlling ascites. Significant overall survival (OS) benefits 
were reported in GOG218 patients with ascites at baseline, however, not in the ITT 
population. This raises questions about the potential role of “progression-driven 
cross-over” in confounding OS trial results. The objective of this study was to use 
decision-analytic modeling to estimate the potential impact of this “cross-over bias” 
in a RCT. Methods: A decision-analytic Markov model with 6 mutually exclu-
sive health states was built simulating OS as reported in GOG218. In the base case 
analysis, a 49 month time horizon was used (trial length). Input parameters were 
based on trial data and published literature. The model was calibrated to estimate 
the amount of patients developing ascites and switching. The model was then used 
estimating the unbiased treatment effect as it would have been observed without 
switching. Results: The model provided similar survival curves as reported. When 
switching treatment was disabled, the relative risk reduction for OS due to BEV 
compared to placebo changed from 11% to 32% over the 49 month time horizon. The 
results were sensitive to changes in the input parameter of switching, developing 
severe ascites and mortality after progression. ConClusions: Decision-analytic 
methods are suitable for describing causal relations and the impact of a potential 
bias. We estimated that about two thirds of the true treatment effect could not be 
captured in the biased data analysis. However, a formal adjustment of the original 
RCT data was not feasible due to lack of clinical trial data describing switching 
patterns. As crossover bias cannot always be avoided by trial design due to ethical 
reasons, we recommend collecting sufficient confounding variables determining 
cross-over so that specific statistical methods for causal-inference can be applied 
to control the cross-over bias.
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Martin Saborido C., Zuluaga Sanchez S.
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objeCtives: To examine the new co-payment scheme for prescribed medications 
introduced in Spain in 2012 and to explore differences in patient and National 
Health Service (NHS) drug cost co-payments between the old and the new schemes, 
using an example in a modelled patient population with coronary heart disease 
(CHD). Methods: The new legislation was researched and the new co-payment 
scheme was summarised in a flowchart. A published economic evaluation of drug-
eluting versus bare metal stents for high-risk patients with CHD was used to calcu-
late co-payments for the total cost of a prescribed drug (clopidogrel) from patients 
and from the NHS. The patient contribution was estimated from the income and 
expected work status of the model’s population. Results: In the new co-payment 
scheme, pharmacy-dispensed drugs are divided into three categories, using the 
Anatomical, Therapeutic, and Chemical classification system: 1) reimbursed with 
reduced contribution (4.26 € per prescription in 2014), 2) reimbursed without reduced 
contribution (ranging from 40% to 60%, depending on declared incomes for active 
workers, and from 10% to 60% for retired people) and 3) not reimbursed. Monthly 
limits for retired people (in 2014) range from 8.26 € to 62 € , with a monthly limit 
of 0.426 € for long-term, chronic conditions. The current, monthly, over-the-coun-
ter price of clopidogrel is 22.92 € . Under the old co-payment scheme, the model 
estimated that the average NHS payment was 19.62 € per patient (86% of the cost). 
Under the new scheme, this amount was estimated at 16.55 € (72%). The NHS con-
tribution decreased by 14%. ConClusions: The new scheme results in a signifi-
cant reduction to drug-related NHS co-payment contributions. This reduction could 
lead to significant changes in incremental cost-effectiveness ratio estimates. It is 
recommended that this adjustment be made in economic evaluations developed 
or adapted for Spain.
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stRatifieD COst-effeCtiveness analysis tO GUiDe GenetiC sCReeninG 
fOR CanCeR Risk
Folse H.J., Dinh T.
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objeCtives: Genetic screening identifies candidates for intensified cancer 
screening and prevention. Due to the high cost of genetic testing, it is impor-
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objeCtives: To compare homogeneous (HMM) versus non-homogeneous Markov 
models (NHMM) for cost-effectiveness analysis (CEA) of routine use of transparent 
dressings containing a chlorhexidine gluconate gel pad versus standard trans-
parent dressings. The antimicrobial dressing protects central vascular accesses 
reducing the risk of catheter-related bloodstream infections (CRBSIs) in intensive 
care units (ICU). The impact of the modeling approach on the decision of adopt-
ing antimicrobial dressings for critically-ill patients is discussed. Methods: 
Comparative clinical efficacy data from a multicentre randomized controlled trial 
(RCT) enrolling 1,879 patients and economical data from micro and macro-costing 
published studies were combined. The HMM and NHMM models were built sepa-
rately using the same sources. The statistical unit was the ICU patient and the ICU 
perspective was chosen. Probabilistic sensitivity analyses (PSA) were conducted 
for both models for comparing the robustness of the CEA results. Results: The 
difference in clinical outcomes between each dressing strategies was statisti-
cally significant with both models while cost differences were not. The PSA with 
the NHMM resulted in 11.8 infections avoided per 1,000 patients (95%CI: [3.85; 
19.64]) and a mean extra cost of € 141 per patient (95%CI: [€ -975; € 1,258]) when 
using antimicrobial dressing. The PSA with the HMM resulted in 6.45 infections 
avoided per 1,000 patients (95%CI: [0.15; 12.75]) and the mean extra cost of € 252 
per patient (95%CI: [€ -924; € 1,428]). ConClusions: The antimicrobial dressings 
are consistently more efficacious in preventing CRBSIs whatever the model used. 
The HMM is less sensitive to simulate the real life of the ICU patients. Regardless 
the model approach chosen the antimicrobial strategy is more efficacious than 
the comparator, but its probability of being cost-effective is comparatively reduced 
with the HMM. Time dependent approach (NHMM) seems to be better adapted to 
model rare events as CRBSIs.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is a major 
cause of end-stage renal disease (ESRD) affecting approximately 4 per 10,000 people 
in Europe. There is a paucity of research regarding the natural history of ADPKD 
progression. This study aimed to utilise the results of a systematic literature review 
characterising predictors of ADPKD progression to construct a natural history dis-
ease model for ADPKD. Methods: An individual patient-level lifetime simulation 
was developed in Microsoft Excel, driven by baseline and time-dependent age, esti-
mated glomerular filtration rate (eGFR) and total kidney volume (TKV). Rates of 
progression were informed by a large naturalistic study. Dialysis modality, transplant 
status and disease-specific mortality were also modelled. Relevant ADPKD compli-
cations were stratified by chronic kidney disease stages. Modification of disease 
progression rate was investigated in order to assess the potential of the model 
for evaluating treatment interventions. Results: On visual inspection, modelled 
and published eGFR trajectories for the general ADPKD patient were consistent 
(median age at ESRD of approximately 55 years). When patients are stratified by 
baseline TKV the model predicts variable rates of progression to ESRD, aligning with 
the assertion that the baseline TKV is the most important prognostic indicator for 
ADPKD progression. Modification of the risk equations to incorporate the impact of 
an intervention has shown promise to estimate important outcomes such as delay 
to ESRD. ConClusions: The model has demonstrated both face and predictive 
validity and is capable of predicting outcomes consistent with those reported in the 
ADPKD literature. It represents the first model capable of informing on important 
clinical outcomes relevant to both clinicians and patients, such as time to ESRD, 
with the potential to evaluate the long-term impact of treatment interventions on 
ADPKD progression.
PRM119
fOReCastinG CanCeR inCiDenCe UsinG GROss DOMestiC PRODUCt
Ayodele O.A.1, Isherwood A.2, Hughes M.2
1Decision Resources Group, Burlington, MA, USA, 2Decision Resources Group, London, UK
objeCtives: To validate the use of change in Gross Domestic Product per capita 
(GDP) as a proxy for forecasting change in cancer risk. Methods: Using data from 
the International Agency for Research on Cancer (IARC) and GDP data from the 
World Bank, the correlation between the incidence of five cancers (breast, prostate, 
lung, liver, and colorectal) in 147 countries for 1993-1997 (midyear 1995), and the 
corresponding GDP was calculated. We used this correlation to retrospectively 
forecast the 2005 incidence for five cancers in four cities (Cali, Colombia; Delhi, 
India; Shanghai, China; St. Petersburg, Russia). The GDP-based forecasts were com-
pared to a control assuming no change in incidence from the IARC incidence data 
for 1998-2002 (midyear 2000). The two forecast estimates with the actual reported 
IARC 2003-2007 incidence data were compared. Results: Overall, the GDP-based 
method correctly forecasts the directional change in incidence in 75% (95% confi-
